Highlights
- •Heparin-induced thrombocytopenia (HIT) in pregnancy, especially in the first trimester, is uncommon
- •Fondaparinux is a reasonable anticoagulation option for HIT in pregnancy
- •Duration of therapeutic anticoagulation for provoked emboli in pregnancy is unclear
- •Involvement of a tertiary center for anticoagulation and obstetrical management for pregnant patients with HIT is recommended
Abstract
Heparin-induced thrombocytopenia in pregnancy is an uncommon phenomenon which rarely
occurs in the first trimester. Therapeutic options and duration of therapeutic anticoagulation
are varied amongst reported published cases. We report a 41-year-old female with confirmed
HIT following anticoagulation with dalteparin for deep vein thrombosis (DVT). She
was treated with therapeutic fondaparinux for 3 months followed by prophylaxis dosage
until delivery and for 6 weeks thereafter. A review of reported cases of the development
of HIT in the first trimester and subsequent clinical management is discussed.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Thrombosis ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Deep venous thrombosis in pregnancy: incidence, pathogenesis and endovascular management.Cardiovasc. Diagn. Ther. 2017; 7S309
- Heparin-induced thrombocytopenia is rare in pregnancy.Am. J. Obstet. Gynecol. 2001; 185: 148-152
- Management and outcome of heparin-induced thrombocytopenia in pregnancy: a systematic review.Cardiovasc. Hematol. Agents Med. Chem. 2015; 13: 92-97
- Fondaparinux in pregnancy: could it be a safe option? A review of the literature.Thromb. Res. 2015; 135: 1049-1051
- Heparin-induced thrombocytopenia during obstetric hospital admissions.Am. J. Perinatol. 2018; 35: 898-903
- Pregnancy associated with lupus anticoagulant and heparin induced thrombocytopenia: management with a low molecular weight heparinoid.Thromb. Res. 1991; 62: 23-29
- Thrombocytopenia, antithrombin deficiency and extensive thromboembolism in pregnancy: treatment with low-molecular-weight heparin.Blood Coagul. Fibrinolysis. 1995; 6: 672-675
- Treatment of heparin induced thrombocytopenia and thrombosis during the first trimester of pregnancy.J. Thromb. Haemost. 2004; 2: 1665-1666
- Heparin-induced thrombocytopenia occurring in the first trimester of pregnancy: successful treatment with lepirudin. A case report.Haematologica. 2006; 91 (ECR40-ECR)
- Successful use of danaparoid in two pregnant women with heart valve prosthesis and heparin-induced thrombocytopenia Type II (HIT).Clin. Appl. Thromb. Hemost. 2009; 15: 461-464
- Hypereosinophilic syndrome with cardiac involvement in a pregnant patient with multiple sclerosis.Tex. Heart Inst. J. 2011; 38: 163
- Successful pregnancy after pulmonary embolism and heparin-induced thrombocytopenia–case report.Clin. Exp. Obstet. Gynecol. 2013; 40: 307-308
- Argatroban therapy for heparin-induced thrombocytopenia during pregnancy in a woman with hereditary antithrombin deficiency.J. Obstet. Gynaecol. Res. 2012; 38: 749-752
- Prosthetic valve thrombosis caused by heparin-induced thrombocytopenia thrombosis during pregnancy.Circ. J. 2013; 78 (CJ-13-0919): 1004-1005
- Apixaban therapy in a pregnant woman with heparin-induced thrombocytopenia and venous thromboembolic events caused by congenital antithrombin deficiency: a case report. Case reports.Women’s Health. 2020; 27: 200-201https://doi.org/10.1016/j.crwh.2020.e00200
- Venous thromboembolism and antithrombotic therapy in pregnancy.J. Obstet. Gynaecol. Can. 2014; 36: 527-553
- Risk of a thrombotic event after the 6-week postpartum period.N. Engl. J. Med. 2014; 370: 1307-1315
- Examining the transplacental passage of apixaban using the dually perfused human placenta.J. Thromb. Haemost. 2016; 14: 1436-1441
Article info
Publication history
Published online: September 13, 2021
Accepted:
September 2,
2021
Received in revised form:
August 31,
2021
Received:
June 1,
2021
Footnotes
☆This case report did not receive any research funding.
Identification
Copyright
© 2021 Elsevier Ltd. All rights reserved.
